Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

Sameh Mosaad Fouda, Ahmed M Bahgat Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt Purpose: The purpose of this study was to compare the efficacy of intravitreal aflibercept and ranibizumab in the treatment of diabetic macular edema (DME) in eyes with moderate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fouda SM, Bahgat AM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Aflibercept Ranibizumab Diabetic macular edema intravitreal injection. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/930b62ad011448ee917c090564d45b6e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:930b62ad011448ee917c090564d45b6e
record_format	dspace
spelling	oai:doaj.org-article:930b62ad011448ee917c090564d45b6e2021-12-02T06:36:47ZIntravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema1177-5483https://doaj.org/article/930b62ad011448ee917c090564d45b6e2017-03-01T00:00:00Zhttps://www.dovepress.com/intravitreal-aflibercept-versus-intravitreal-ranibizumab-for-the-treat-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Sameh Mosaad Fouda, Ahmed M Bahgat Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt Purpose: The purpose of this study was to compare the efficacy of intravitreal aflibercept and ranibizumab in the treatment of diabetic macular edema (DME) in eyes with moderate visual loss.Patients and methods: This study is a randomized prospective study. Seventy eyes with DME were divided into two groups (each containing 35 eyes). Eyes in group I were treated with intravitreal injection of 2 mg/0.05 mL aflibercept and eyes in group II were treated with intravitreal injection of 0.5 mg/0.1 mL ranibizumab. All the eyes had three successive injections as a loading dose (with 1 month interval), and then the patients were followed up monthly for 12 months. The outcomes of the study were visual acuity, central macular thickness (CMT), and the number of re-injections of the drug.Results: Mean age of the patients in group I was 55.05±4.7 years and in group II was 56.64±5.8 years (P=0.17). The mean baseline best corrected visual acuity (BCVA) of eyes treated with aflibercept was 0.17±0.05 and with ranibizumab was 0.18±0.04 (P=0.9). BCVA was improved in both the groups at the end of the follow-up period and was found to be 0.42±0.28 and 0.37±0.23, respectively (P=0.27). The mean baseline CMT of eyes in group I was 465.29±33.7 µm and in group II was 471.5±34.4 µm (P=0.65). CMT decreased in both the groups to 360.8±85.7 µm and 387.3±87.8 µm, respectively (P=0.2). The mean number of drug re-injection was 2.62±0.68 and 3.03±0.95 in both the groups, respectively (P=0.02).Conclusion: Aflibercept and ranibizumab have the same efficacy in the treatment of DME in eyes with moderate visual loss but with less number of drug re-injection and less treatment burden with aflibercept (2.62±0.68 versus 3.03±0.95). Keywords: aflibercept, ranibizumab, diabetic macular edema, intravitreal injectionFouda SMBahgat AMDove Medical PressarticleAfliberceptRanibizumabDiabetic macular edemaintravitreal injection.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 567-571 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aflibercept Ranibizumab Diabetic macular edema intravitreal injection. Ophthalmology RE1-994
spellingShingle	Aflibercept Ranibizumab Diabetic macular edema intravitreal injection. Ophthalmology RE1-994 Fouda SM Bahgat AM Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
description	Sameh Mosaad Fouda, Ahmed M Bahgat Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt Purpose: The purpose of this study was to compare the efficacy of intravitreal aflibercept and ranibizumab in the treatment of diabetic macular edema (DME) in eyes with moderate visual loss.Patients and methods: This study is a randomized prospective study. Seventy eyes with DME were divided into two groups (each containing 35 eyes). Eyes in group I were treated with intravitreal injection of 2 mg/0.05 mL aflibercept and eyes in group II were treated with intravitreal injection of 0.5 mg/0.1 mL ranibizumab. All the eyes had three successive injections as a loading dose (with 1 month interval), and then the patients were followed up monthly for 12 months. The outcomes of the study were visual acuity, central macular thickness (CMT), and the number of re-injections of the drug.Results: Mean age of the patients in group I was 55.05±4.7 years and in group II was 56.64±5.8 years (P=0.17). The mean baseline best corrected visual acuity (BCVA) of eyes treated with aflibercept was 0.17±0.05 and with ranibizumab was 0.18±0.04 (P=0.9). BCVA was improved in both the groups at the end of the follow-up period and was found to be 0.42±0.28 and 0.37±0.23, respectively (P=0.27). The mean baseline CMT of eyes in group I was 465.29±33.7 µm and in group II was 471.5±34.4 µm (P=0.65). CMT decreased in both the groups to 360.8±85.7 µm and 387.3±87.8 µm, respectively (P=0.2). The mean number of drug re-injection was 2.62±0.68 and 3.03±0.95 in both the groups, respectively (P=0.02).Conclusion: Aflibercept and ranibizumab have the same efficacy in the treatment of DME in eyes with moderate visual loss but with less number of drug re-injection and less treatment burden with aflibercept (2.62±0.68 versus 3.03±0.95). Keywords: aflibercept, ranibizumab, diabetic macular edema, intravitreal injection
format	article
author	Fouda SM Bahgat AM
author_facet	Fouda SM Bahgat AM
author_sort	Fouda SM
title	Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
title_short	Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
title_full	Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
title_fullStr	Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
title_full_unstemmed	Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
title_sort	intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/930b62ad011448ee917c090564d45b6e
work_keys_str_mv	AT foudasm intravitrealafliberceptversusintravitrealranibizumabforthetreatmentofdiabeticmacularedema AT bahgatam intravitrealafliberceptversusintravitrealranibizumabforthetreatmentofdiabeticmacularedema
_version_	1718399826514673664

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

Ejemplares similares